Disease Overview
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: ● Clinical > ● Mechanistic > ● Correlative.
CACNA1A
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| PREGABALIN | ~ modulates | Mechanistic | DGIdb | |
| TERODILINE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| GABAPENTIN | ~ modulates | Mechanistic | DGIdb | |
| CELECOXIB | ? unclear | Mechanistic | DGIdb | |
| ELPETRIGINE | ↓ inhibits | Mechanistic | DGIdb | |
| NISOLDIPINE | ? unclear | Mechanistic | DGIdb | |
| BEPRIDIL | ? unclear | Mechanistic | DGIdb | |
| IMAGABALIN | ~ modulates | Mechanistic | DGIdb | |
| ATAGABALIN | ~ modulates | Mechanistic | DGIdb | |
| ANTIDEPRESSANT AGENT | ? unclear | Mechanistic | DGIdb | |
| PHLOROGLUCINOL | ↓ inhibits | Mechanistic | DGIdb | |
| GABAPENTIN ENACARBIL | ~ modulates | Mechanistic | DGIdb | |
| SULOCTIDIL | ↓ inhibits | Mechanistic | DGIdb | |
| BEPRIDIL HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| FLUNARIZINE | ? unclear | Mechanistic | DGIdb | |
| TERODILINE | ? unclear | Mechanistic | Open Targets | |
| CHEMBL2206242 | ↑ activates | Mechanistic | 8800.0 nM (EC50) | ChEMBL |
| CHEMBL2017291 | ↓ inhibits | Mechanistic | 1260.0 nM (IC50) | ChEMBL |
CALCA
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| NATEGLINIDE | ? unclear | Mechanistic | DGIdb | |
| BUDIODARONE | ? unclear | Mechanistic | DGIdb | |
| CIZOLIRTINE | ? unclear | Mechanistic | DGIdb | |
| IH636 GRAPE SEED PROANTHOCYANIDIN EXTRACT | ? unclear | Mechanistic | DGIdb | |
| AMIODARONE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| INCOBOTULINUMTOXINA | ? unclear | Mechanistic | DGIdb | |
| RANITIDINE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| AMIFAMPRIDINE | ? unclear | Mechanistic | DGIdb | |
| DRONEDARONE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL42661 | ? unclear | Mechanistic | DGIdb | |
| AZIMILIDE | ? unclear | Mechanistic | DGIdb | |
| PINACIDIL | ? unclear | Mechanistic | DGIdb | |
| FENTANYL CITRATE | ? unclear | Mechanistic | DGIdb | |
| TESTOSTERONE PROPIONATE | ? unclear | Mechanistic | DGIdb | |
| FREMANEZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| SULCARDINE SULFATE | ? unclear | Mechanistic | DGIdb | |
| PREDNISONE | ? unclear | Mechanistic | DGIdb | |
| DOFETILIDE | ? unclear | Mechanistic | DGIdb | |
| ANDOLAST | ? unclear | Mechanistic | DGIdb | |
| IBUTILIDE | ? unclear | Mechanistic | DGIdb | |
| EPTINEZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1563246 | ? unclear | Mechanistic | DGIdb | |
| MINOXIDIL | ? unclear | Mechanistic | DGIdb | |
| DALFAMPRIDINE | ? unclear | Mechanistic | DGIdb | |
| BIMAKALIM | ? unclear | Mechanistic | DGIdb | |
| GALCANEZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| DIAZOXIDE | ? unclear | Mechanistic | DGIdb |
CALCRL
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| DAVALINTIDE | ↑ activates | Mechanistic | DGIdb | |
| FREMANEZUMAB | ? unclear | Mechanistic | DGIdb | |
| MK-3207 | ? unclear | Mechanistic | DGIdb | |
| ZAVEGEPANT HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| TELCAGEPANT | ↓ inhibits | Mechanistic | DGIdb | |
| RIMEGEPANT | ↓ inhibits | Mechanistic | DGIdb | |
| CALCITONIN GENE-RELATED PEPTIDE | ? unclear | Mechanistic | DGIdb | |
| ERENUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| OLCEGEPANT | ↓ inhibits | Mechanistic | DGIdb | |
| BI-44370 | ↓ inhibits | Mechanistic | DGIdb | |
| RIMEGEPANT SULFATE | ↓ inhibits | Mechanistic | DGIdb | |
| MK3207 | ↓ inhibits | Mechanistic | DGIdb | |
| ATOGEPANT | ↓ inhibits | Mechanistic | DGIdb | |
| UBROGEPANT | ↓ inhibits | Mechanistic | DGIdb | |
| GALCANEZUMAB | ? unclear | Mechanistic | DGIdb | |
| ZAVEGEPANT | ↓ inhibits | Mechanistic | DGIdb | |
| CHEMBL329678 | ↓ inhibits | Mechanistic | 41000.0 nM (IC50) | ChEMBL |
| CHEMBL316211 | ↓ inhibits | Mechanistic | 96000.0 nM (IC50) | ChEMBL |
| CHEMBL88111 | ↓ inhibits | Mechanistic | 74000.0 nM (IC50) | ChEMBL |
| CHEMBL88441 | ↓ inhibits | Mechanistic | 12000.0 nM (IC50) | ChEMBL |
| CHEMBL313797 | ↓ inhibits | Mechanistic | 17000.0 nM (IC50) | ChEMBL |
| CHEMBL87174 | ↓ inhibits | Mechanistic | 33000.0 nM (IC50) | ChEMBL |
| CHEMBL419684 | ↓ inhibits | Mechanistic | 5900.0 nM (IC50) | ChEMBL |
| CHEMBL314992 | ↓ inhibits | Mechanistic | 5200.0 nM (IC50) | ChEMBL |
| CHEMBL89148 | ↓ inhibits | Mechanistic | 9900.0 nM (IC50) | ChEMBL |
| CHEMBL88582 | ↓ inhibits | Mechanistic | 37000.0 nM (IC50) | ChEMBL |
| CHEMBL3037882 | ↓ inhibits | Mechanistic | 2.0 nM (IC50) | ChEMBL |
| CHEMBL1794015 | ↓ inhibits | Mechanistic | 185.0 nM (IC50) | ChEMBL |
| CHEMBL2369742 | ↓ inhibits | Mechanistic | 4.0 nM (IC50) | ChEMBL |
| CHEMBL2369452 | ↓ inhibits | Mechanistic | 9.0 nM (IC50) | ChEMBL |
| CHEMBL2369457 | ↓ inhibits | Mechanistic | 11.2 nM (IC50) | ChEMBL |
| CHEMBL2369465 | ↓ inhibits | Mechanistic | 25.0 nM (IC50) | ChEMBL |
| CHEMBL2369463 | ↓ inhibits | Mechanistic | 2.3 nM (IC50) | ChEMBL |
| CHEMBL525571 | ↓ inhibits | Mechanistic | 2.3 nM (IC50) | ChEMBL |
| CHEMBL2369458 | ↓ inhibits | Mechanistic | 6.9 nM (IC50) | ChEMBL |
| CHEMBL2369459 | ↓ inhibits | Mechanistic | 2.0 nM (IC50) | ChEMBL |
| CHEMBL2369464 | ↓ inhibits | Mechanistic | 20.2 nM (IC50) | ChEMBL |
| CHEMBL2369454 | ↓ inhibits | Mechanistic | 3.0 nM (IC50) | ChEMBL |
| CHEMBL404977 | ↓ inhibits | Mechanistic | 24000.0 nM (IC50) | ChEMBL |
| CHEMBL216710 | ↓ inhibits | Mechanistic | 1200.0 nM (IC50) | ChEMBL |
Showing top 40 of 159 agents ranked by evidence tier.
HTR1B
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| FLUPHENAZINE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| ALMOTRIPTAN MALATE | ↑ activates | Mechanistic | DGIdb | |
| TRELANSERIN | ↓ inhibits | Mechanistic | DGIdb | |
| SUMATRIPTAN | ↑ activates | Mechanistic | 7.7 nM (Ki) | DGIdb |
| RIZATRIPTAN BENZOATE | ↑ activates | Mechanistic | DGIdb | |
| DONITRIPTAN | ↑ activates | Mechanistic | DGIdb | |
| AMISULPRIDE | ↓ inhibits | Mechanistic | DGIdb | |
| NXN-188 | ? unclear | Mechanistic | DGIdb | |
| ELTOPRAZINE | ? unclear | Mechanistic | DGIdb | |
| FROVATRIPTAN | ? unclear | Mechanistic | DGIdb | |
| CITALOPRAM | ? unclear | Mechanistic | DGIdb | |
| NARATRIPTAN HYDROCHLORIDE | ↑ activates | Mechanistic | DGIdb | |
| FROVATRIPTAN SUCCINATE | ↑ activates | Mechanistic | DGIdb | |
| ALMOTRIPTAN | ? unclear | Mechanistic | DGIdb | |
| ZOLMITRIPTAN | ↑ activates | Mechanistic | 6.166 nM (IC50) | DGIdb |
| ELETRIPTAN | ↑ activates | Mechanistic | DGIdb | |
| ERGOTAMINE | ? unclear | Mechanistic | DGIdb | |
| GSK163090 | ↓ inhibits | Mechanistic | DGIdb | |
| NEFAZODONE | ? unclear | Mechanistic | DGIdb | |
| LITHIUM | ? unclear | Mechanistic | DGIdb | |
| CLOMIPRAMINE | ? unclear | Mechanistic | DGIdb | |
| ERGOLOID MESYLATES, USP | ↑ activates | Mechanistic | DGIdb | |
| ASENAPINE | ? unclear | Mechanistic | DGIdb | |
| DIHYDROERGOTAMINE MESYLATE | ? unclear | Mechanistic | DGIdb | |
| PAROXETINE HYDROCHLORIDE, HEMIHYDRATE | ? unclear | Mechanistic | DGIdb | |
| LIOTHYRONINE | ? unclear | Mechanistic | DGIdb | |
| VORTIOXETINE HYDROBROMIDE | ? unclear | Mechanistic | DGIdb | |
| NARATRIPTAN | ? unclear | Mechanistic | DGIdb | |
| ZIMELDINE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| DEXFENFLURAMINE HYDROCHLORIDE | ↑ activates | Mechanistic | DGIdb | |
| DRUGSATFDA.NDA:016727 | ? unclear | Mechanistic | DGIdb | |
| OLANZAPINE | ? unclear | Mechanistic | DGIdb | |
| ELZASONAN HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| FLUOXETINE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| ELZASONAN | ? unclear | Mechanistic | Open Targets | |
| ELETRIPTAN HYDROBROMIDE | ? unclear | Mechanistic | Open Targets | |
| RIZATRIPTAN | ? unclear | Mechanistic | Open Targets | |
| DEXFENFLURAMINE | ? unclear | Mechanistic | Open Targets | |
| ERGOLOID MESYLATES | ? unclear | Mechanistic | Open Targets | |
| ZIMELDINE | ? unclear | Mechanistic | Open Targets |
Showing top 40 of 198 agents ranked by evidence tier.
HTR1D
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| FROVATRIPTAN | ? unclear | Mechanistic | DGIdb | |
| TONABERSAT | ? unclear | Mechanistic | DGIdb | |
| SUMATRIPTAN | ↑ activates | Mechanistic | 39.81 nM (IC50) | DGIdb |
| ELZASONAN HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| ZOLMITRIPTAN | ↑ activates | Mechanistic | DGIdb | |
| ELETRIPTAN | ↑ activates | Mechanistic | DGIdb | |
| ALMOTRIPTAN MALATE | ↑ activates | Mechanistic | DGIdb | |
| ERGOTAMINE | ? unclear | Mechanistic | DGIdb | |
| ERGOTAMINE TARTRATE | ↑ activates | Mechanistic | DGIdb | |
| ALMOTRIPTAN | ? unclear | Mechanistic | DGIdb | |
| NARATRIPTAN | ? unclear | Mechanistic | DGIdb | |
| OLANZAPINE | ? unclear | Mechanistic | DGIdb | |
| NARATRIPTAN HYDROCHLORIDE | ↑ activates | Mechanistic | DGIdb | |
| DONITRIPTAN | ↑ activates | Mechanistic | DGIdb | |
| RIZATRIPTAN BENZOATE | ↑ activates | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL490417 | ? unclear | Mechanistic | DGIdb | |
| FENFLURAMINE HYDROCHLORIDE | ↑ activates | Mechanistic | DGIdb | |
| AMISULPRIDE | ↓ inhibits | Mechanistic | DGIdb | |
| PIROMELATINE | ? unclear | Mechanistic | DGIdb | |
| GSK163090 | ↓ inhibits | Mechanistic | DGIdb | |
| FROVATRIPTAN SUCCINATE | ↑ activates | Mechanistic | DGIdb | |
| NXN-188 | ? unclear | Mechanistic | DGIdb | |
| ZIMELDINE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| DEXFENFLURAMINE HYDROCHLORIDE | ↑ activates | Mechanistic | DGIdb | |
| ZIPRASIDONE | ? unclear | Mechanistic | DGIdb | |
| DIHYDROERGOTAMINE MESYLATE | ↑ activates | Mechanistic | DGIdb | |
| DEXFENFLURAMINE | ? unclear | Mechanistic | Open Targets | |
| ELETRIPTAN HYDROBROMIDE | ? unclear | Mechanistic | Open Targets | |
| DIHYDROERGOTAMINE | ? unclear | Mechanistic | Open Targets | |
| SUMATRIPTAN SUCCINATE | ? unclear | Mechanistic | Open Targets | |
| RIZATRIPTAN | ? unclear | Mechanistic | 79.43 nM (IC50) | Open Targets |
| FENFLURAMINE | ? unclear | Mechanistic | Open Targets | |
| ELZASONAN | ? unclear | Mechanistic | Open Targets | |
| ZIMELDINE | ? unclear | Mechanistic | Open Targets | |
| GR-127935 | ↓ inhibits | Mechanistic | 0.7 nM (Ki) | ChEMBL |
| CHEMBL321818 | ↓ inhibits | Mechanistic | 2.0 nM (Ki) | ChEMBL |
| CHEMBL292779 | ↓ inhibits | Mechanistic | 0.6 nM (IC50) | ChEMBL |
| CHEMBL325131 | ↓ inhibits | Mechanistic | 340.0 nM (Ki) | ChEMBL |
| CHEMBL107772 | ↓ inhibits | Mechanistic | 3.6 nM (Ki) | ChEMBL |
| CHEMBL304857 | ↓ inhibits | Mechanistic | 2.2 nM (IC50) | ChEMBL |
Showing top 40 of 153 agents ranked by evidence tier.
HTR1F
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| LASMIDITAN SUCCINATE | ↑ activates | Mechanistic | DGIdb | |
| SUMATRIPTAN | ? unclear | Mechanistic | 25.7 nM (Ki) | DGIdb |
| ZOLMITRIPTAN | ? unclear | Mechanistic | DGIdb | |
| AMISULPRIDE | ↓ inhibits | Mechanistic | DGIdb | |
| ALMOTRIPTAN MALATE | ↑ activates | Mechanistic | DGIdb | |
| [3H]LY334370 | ? unclear | Mechanistic | DGIdb | |
| DEXFENFLURAMINE HYDROCHLORIDE | ↑ activates | Mechanistic | DGIdb | |
| ELETRIPTAN | ↑ activates | Mechanistic | DGIdb | |
| ZIMELDINE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| NARATRIPTAN | ? unclear | Mechanistic | DGIdb | |
| LASMIDITAN | ↑ activates | Mechanistic | 87.84 nM (IC50) | DGIdb |
| ELETRIPTAN HYDROBROMIDE | ? unclear | Mechanistic | Open Targets | |
| ALMOTRIPTAN | ? unclear | Mechanistic | Open Targets | |
| ZIMELDINE | ? unclear | Mechanistic | Open Targets | |
| DEXFENFLURAMINE | ? unclear | Mechanistic | Open Targets | |
| CHEMBL292759 | ↓ inhibits | Mechanistic | 316.23 nM (Ki) | ChEMBL |
| CHEMBL29846 | ↓ inhibits | Mechanistic | 251.19 nM (Ki) | ChEMBL |
| CHEMBL29433 | ↓ inhibits | Mechanistic | 316.23 nM (Ki) | ChEMBL |
| CHEMBL282971 | ↓ inhibits | Mechanistic | 199.53 nM (Ki) | ChEMBL |
| CHEMBL292779 | ↓ inhibits | Mechanistic | 3800.0 nM (IC50) | ChEMBL |
| CHEMBL178066 | ↓ inhibits | Mechanistic | 8.2 nM (Ki) | ChEMBL |
| CHEMBL177258 | ↓ inhibits | Mechanistic | 3.1 nM (Ki) | ChEMBL |
| CHEMBL369705 | ↓ inhibits | Mechanistic | 2.9 nM (Ki) | ChEMBL |
| CHEMBL177238 | ↓ inhibits | Mechanistic | 3.0 nM (Ki) | ChEMBL |
| CHEMBL101690 | ↓ inhibits | Mechanistic | 1.6 nM (Ki) | ChEMBL |
| CHEMBL103479 | ↓ inhibits | Mechanistic | 7.6 nM (Ki) | ChEMBL |
| CHEMBL369391 | ↓ inhibits | Mechanistic | 13.5 nM (Ki) | ChEMBL |
| CHEMBL173949 | ↓ inhibits | Mechanistic | 2.3 nM (Ki) | ChEMBL |
| CHEMBL2110300 | ↓ inhibits | Mechanistic | 363.08 nM (IC50) | ChEMBL |
| CHEMBL432713 | ↓ inhibits | Mechanistic | 3.162 nM (Ki) | ChEMBL |
| CHEMBL92139 | ↓ inhibits | Mechanistic | 3.9 nM (Ki) | ChEMBL |
| CHEMBL76237 | ↓ inhibits | Mechanistic | 2500.0 nM (Ki) | ChEMBL |
| CHEMBL263700 | ↓ inhibits | Mechanistic | 29.0 nM (Ki) | ChEMBL |
| CHEMBL126340 | ↓ inhibits | Mechanistic | 570.0 nM (Ki) | ChEMBL |
| CHEMBL125745 | ↓ inhibits | Mechanistic | 47.0 nM (Ki) | ChEMBL |
| CHEMBL317535 | ↓ inhibits | Mechanistic | 2000.0 nM (Ki) | ChEMBL |
| CHEMBL93868 | ↓ inhibits | Mechanistic | 770.0 nM (Ki) | ChEMBL |
| CHEMBL321133 | ↓ inhibits | Mechanistic | 16.0 nM (Ki) | ChEMBL |
| CHEMBL104753 | ↓ inhibits | Mechanistic | 7.4 nM (Ki) | ChEMBL |
| CHEMBL105478 | ↓ inhibits | Mechanistic | 18.0 nM (Ki) | ChEMBL |
Showing top 40 of 139 agents ranked by evidence tier.
NOS3
Pipeline results not yet available for this target. Run the pipeline to populate.
RAMP1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| DAVALINTIDE | ↑ activates | Mechanistic | DGIdb | |
| ZAVEGEPANT | ↓ inhibits | Mechanistic | DGIdb | |
| PRAMLINTIDE ACETATE | ↑ activates | Mechanistic | DGIdb | |
| PRAMLINTIDE | ? unclear | Mechanistic | 23.44 nM (EC50) | DGIdb |
| CHEMBL264010 | ↓ inhibits | Mechanistic | 14.0 nM (Ki) | ChEMBL |
| CHEMBL406459 | ↓ inhibits | Mechanistic | 76.8 nM (Ki) | ChEMBL |
| CHEMBL2371892 | ↓ inhibits | Mechanistic | 70.5 nM (Ki) | ChEMBL |
| CHEMBL2371890 | ↓ inhibits | Mechanistic | 6.31 nM (Kd) | ChEMBL |
| CHEMBL385986 | ↓ inhibits | Mechanistic | 25.12 nM (Kd) | ChEMBL |
| CHEMBL386763 | ↓ inhibits | Mechanistic | 10.0 nM (Kd) | ChEMBL |
| CHEMBL2371891 | ↓ inhibits | Mechanistic | 31.62 nM (Kd) | ChEMBL |
| CHEMBL427759 | ↓ inhibits | Mechanistic | 0.7 nM (Ki) | ChEMBL |
| CHEMBL208148 | ↓ inhibits | Mechanistic | 4250.0 nM (Ki) | ChEMBL |
| CHEMBL381585 | ↓ inhibits | Mechanistic | 83.0 nM (Ki) | ChEMBL |
| CHEMBL381798 | ↓ inhibits | Mechanistic | 2370.0 nM (Ki) | ChEMBL |
| CHEMBL381710 | ↓ inhibits | Mechanistic | 61.0 nM (Ki) | ChEMBL |
| CHEMBL424864 | ↓ inhibits | Mechanistic | 44.0 nM (Ki) | ChEMBL |
| CHEMBL380514 | ↓ inhibits | Mechanistic | 1060.0 nM (Ki) | ChEMBL |
| CHEMBL211052 | ↓ inhibits | Mechanistic | 897.0 nM (Ki) | ChEMBL |
| CHEMBL207186 | ↓ inhibits | Mechanistic | 2200.0 nM (Ki) | ChEMBL |
| CHEMBL379686 | ↓ inhibits | Mechanistic | 8400.0 nM (Ki) | ChEMBL |
| OLCEGEPANT | ↓ inhibits | Mechanistic | 0.1 nM (IC50) | ChEMBL |
| CHEMBL235457 | ↓ inhibits | Mechanistic | 35.0 nM (Ki) | ChEMBL |
| CHEMBL235456 | ↓ inhibits | Mechanistic | 266.0 nM (Ki) | ChEMBL |
| CHEMBL238011 | ↓ inhibits | Mechanistic | 65.0 nM (IC50) | ChEMBL |
| CHEMBL392132 | ↓ inhibits | Mechanistic | 29.0 nM (Ki) | ChEMBL |
| CHEMBL394229 | ↓ inhibits | Mechanistic | 29.0 nM (Ki) | ChEMBL |
| CHEMBL235237 | ↓ inhibits | Mechanistic | 2.0 nM (Ki) | ChEMBL |
| CHEMBL429262 | ↓ inhibits | Mechanistic | 25.0 nM (Ki) | ChEMBL |
| CHEMBL235015 | ↓ inhibits | Mechanistic | 5828.0 nM (Ki) | ChEMBL |
| CHEMBL393823 | ↓ inhibits | Mechanistic | 31.0 nM (Ki) | ChEMBL |
| CHEMBL428547 | ↓ inhibits | Mechanistic | 689.0 nM (Ki) | ChEMBL |
| CHEMBL395599 | ↓ inhibits | Mechanistic | 934.0 nM (Ki) | ChEMBL |
| CHEMBL397054 | ↓ inhibits | Mechanistic | 1993.0 nM (Ki) | ChEMBL |
| CHEMBL236936 | ↓ inhibits | Mechanistic | 11100.0 nM (Ki) | ChEMBL |
| CHEMBL393523 | ↓ inhibits | Mechanistic | 1800.0 nM (Ki) | ChEMBL |
| CHEMBL234989 | ↓ inhibits | Mechanistic | 7800.0 nM (Ki) | ChEMBL |
| CHEMBL238203 | ↓ inhibits | Mechanistic | 3700.0 nM (Ki) | ChEMBL |
| CHEMBL236516 | ↓ inhibits | Mechanistic | 471.0 nM (IC50) | ChEMBL |
| CHEMBL2035986 | ↓ inhibits | Mechanistic | 0.25 nM (Ki) | ChEMBL |
Showing top 40 of 144 agents ranked by evidence tier.
TRPV1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| STREPTOZOCIN | ? unclear | Mechanistic | DGIdb | |
| BENZYL ISOTHIOCYANATE | ? unclear | Mechanistic | DGIdb | |
| ACETAMINOPHEN | ↑ activates | Mechanistic | DGIdb | |
| POLYGODIAL | ? unclear | Mechanistic | DGIdb | |
| PROPOFOL | ? unclear | Mechanistic | DGIdb | |
| SAF312 | ↓ inhibits | Mechanistic | DGIdb | |
| GRC-15300 | ? unclear | Mechanistic | DGIdb | |
| AZD1386 | ↓ inhibits | Mechanistic | DGIdb | |
| TIVANISIRAN | ↓ inhibits | Mechanistic | DGIdb | |
| MAVATREP | ↓ inhibits | Mechanistic | DGIdb | |
| MR-1817 | ↓ inhibits | Mechanistic | DGIdb | |
| FERRUGINENE B | ? unclear | Mechanistic | DGIdb | |
| CAPSAICIN | ↑ activates | Mechanistic | 19.95 nM (EC50) | DGIdb |
| RECOMBINANT TUMOR NECROSIS FACTOR FAMILY PROTEIN | ? unclear | Mechanistic | DGIdb | |
| PHENETHYLISOTHIOCYANATE | ? unclear | Mechanistic | DGIdb | |
| VOACANGINE | ? unclear | Mechanistic | DGIdb | |
| RESINIFERATOXIN | ↑ activates | Mechanistic | 23.1 nM (Ki) | DGIdb |
| DWP05195 | ↓ inhibits | Mechanistic | DGIdb | |
| XEN-D0501 | ↓ inhibits | Mechanistic | DGIdb | |
| PAC-14028 | ↓ inhibits | Mechanistic | DGIdb | |
| SB-705498 | ↓ inhibits | Mechanistic | DGIdb | |
| MASOPROCOL | ? unclear | Mechanistic | DGIdb | |
| ALLYL ISOTHIOCYANATE | ? unclear | Mechanistic | DGIdb | |
| NGD-8243 | ↓ inhibits | Mechanistic | DGIdb | |
| GRC-6211 | ↓ inhibits | Mechanistic | DGIdb | |
| RESERPINE | ? unclear | Mechanistic | DGIdb | |
| NABIXIMOLS | ? unclear | Mechanistic | DGIdb | |
| A425619 | ? unclear | Mechanistic | DGIdb | |
| PHE377 | ↓ inhibits | Mechanistic | DGIdb | |
| ANTISENSE OLIGONUCLEOTIDES | ? unclear | Mechanistic | DGIdb | |
| WORTMANNIN | ? unclear | Mechanistic | DGIdb | |
| JTS-653 | ↓ inhibits | Mechanistic | DGIdb | |
| LEVODOPA | ? unclear | Mechanistic | DGIdb | |
| AMG517 | ↓ inhibits | Mechanistic | DGIdb | |
| CAPSAZEPINE | ? unclear | Mechanistic | 120.0 nM (Ki) | DGIdb |
| ZUCAPSAICIN | ↑ activates | Mechanistic | DGIdb | |
| INDOMETHACIN | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL191534 | ? unclear | Mechanistic | DGIdb | |
| ABT-102 | ↓ inhibits | Mechanistic | DGIdb | |
| ISOPROPYL ISOTHIOCYANATE | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 160 agents ranked by evidence tier.
Recruiting and recently completed trials from ClinicalTrials.gov. Data retrieved 2026-07-03.
The study of the ability to predict pain in a migraine attack, through premonitory symptoms and through an ambulatory monitoring device through real-time recording of hemodynamic variables, is one of the strategic lines of research of the unit. of Headaches at the Hospital de La Princesa since 2013 ...
This is a double-blind, randomized, multicenter, outpatient evaluation of the efficacy, safety, and tolerability of elismetrep, as compared with placebo, in the acute treatment of migraine.
Being able to predict each patients response to a specific treatment can mean a significant improvement in socioeconomic costs, but above all in their quality of life. With the present study, the investigators aim to analyze in a combined way different clinical, biological and neuroimaging variables...
The purpose of this study is to prospectively investigate the temporal sequence of premonitory symptoms across multiple migraine attacks.
A migraine is a moderate to severe headache on one side of the head that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. The main goal of the study is to evaluate the tolerability (how patients handle the study treatment) and safety of atogepant ...
The purpose of the study is to assess the biochemical and clinical effects of omega-3 polyunsaturated fatty acid (PUFA) supplementation in youth suffering from migraine, including its effects on migraine disability, psychological distress, and overall quality of life. This study duration 12 weeks.
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.
The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and adolescents ≥ 6 to \<18 years with episodic migraine.
Preventive pharmacologic therapies for migraine aim to reduce attack frequency and duration and improve quality of life; however, their use, overall benefit and adherence are often limited. Remote electrical neuromodulation (REN) is a non-invasive FDA-cleared wearable device for acute and/or prevent...
A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. A number of treatments are available for adults with migraine but there are limited approved...
Acute treatments for migraine may not provide sufficient pain relief after an initial dose, and a second dose of a given medication may be needed to fully abort an attack. International Headache Society (IHS) global practice recommendations for the Acute Treatment of Migraine suggest a second dose o...
This study will evaluate the efficacy and safety of EVO756 against placebo in adults with migraine.
The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to \< 18 years of age).
A migraine is a moderate to severe headache typically on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. Menstrual migraine (MM) is defined as migraine attacks that occur within the perim...
This study aims at characterizing the effectiveness of rimegepant as an acute migraine treatment in a real world setting on two aspects: * Consistency of response to rimegepant across multiple attacks * Effectiveness of rimegepant in users taking concomitant migraine preventive medications, namely ...
Searched directly from “Migraine” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 9-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).
60 agents shown (approved or with trial evidence) — 53 not found by the gene-target search above.
Dihydroergotamine
Approved · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT05337254 NCT05337254 NCT05337254
TMS system MagPro x100, Tonica Elektronik A/S, DenmarkNOT in gene-target list
· 2 trials · source: ClinicalTrials.gov
NCT01501045 NCT01501045
Rimegepant
Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT06439628 NCT03237845
Frovatriptan
Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT00644033 NCT00644033
PRT-064040 nasal sprayNOT in gene-target list
· 2 trials · source: ClinicalTrials.gov
NCT07016516 NCT07016516
therapeutic ultrasoundNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT03459495
placebo ultrasoundNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT03459495
SPHERENOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT02710942
PRISMNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT02710942
MAbsNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT06549270
topiramateNOT in gene-target list
Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00210873
"Investigational"Auto-injector (sumatriptan succinate)NOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT00510419
IbudilastNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT01389193
almotriptan malate
Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00210509
Rizatriptan 5 mgNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT01286207
Rizatriptan 10 mgNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT01286207
Standard CareNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT01286207
Percutaneous neurostimulationNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT03434652
Galcanezumab
Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT02163993
TEV-48125NOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT03303092
TEV-48125 or placeboNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT03303092
Occipital Nerve StimulationNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT00200109
KetamineNOT in gene-target list
Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT02697071
Normal SalineNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT02697071
AMG334NOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT03927144
Oral ProphylacticNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT03927144
Fremanezumab
Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT04464707
Occipital nerve stimulation ONNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT00407992
Occipital nerve stimulation offNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT00407992
erenumab-aooeNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT06150781
Home-Based Vestibular RehabilitationNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT07493005
Virtual Reality-Based Vestibular RehabilitationNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT07493005
Rimegepant 75 MGNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT05709106
DFN-02NOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT02279082
Rimegepant/BHV3000NOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT04649242
Matching placeboNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT04649242
Conservative treatmentNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT06953622
Antipaletet drugNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT06953622
Patent Foramen Ovale ClosureNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT06953622
ChronotypeNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT04553445
Green exerciseNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT04553445
Botulinum toxin type ANOT in gene-target list
Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT03381261
Lidocaine 2 % PharmacopunctureNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT07067853
propranolol 20mgNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT07067853
Palmitoylethanolamide sold as Levagen +NOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT05046522
Placebo comparator - maltodextrin and microcrystalline cellulose mixNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT05046522
Lasmiditan 50mgNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT04218162
Lasmiditan 100mgNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT04218162
Vestibular Migraine Education / Awareness SessionNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT07469748
OnabotulinumtoxinANOT in gene-target list
Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT01071096
SalineNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT01071096
Cognitive, Relaxation, Exercise TherapyNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT00551980
DFN-15 Dose A (treatment A)NOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT02472418
DFN-15 Dose B (treatment B)NOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT02472418
Eptinezumab
Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT07035197
Active partial rebreathing deviceNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT03472417
Dummy partial rebreathing deviceNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT03472417
Active drug for chronic migraine treatment.NOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT07071506
Placebo Subcutaneous injectionNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT07071506
CBT Individual PsychotherapyNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT02870725